Compare DHX & PRLD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | DHX | PRLD |
|---|---|---|
| Founded | 1991 | 2016 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Business Services | Medicinal Chemicals and Botanical Products |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 81.1M | 69.1M |
| IPO Year | 2007 | 2020 |
| Metric | DHX | PRLD |
|---|---|---|
| Price | $1.59 | $1.71 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 2 | 3 |
| Target Price | ★ $4.75 | $4.00 |
| AVG Volume (30 Days) | 283.2K | ★ 405.6K |
| Earning Date | 11-10-2025 | 11-12-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $131,236,000.00 | $10,500,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ 250.00 |
| 52 Week Low | $1.21 | $0.61 |
| 52 Week High | $3.34 | $4.22 |
| Indicator | DHX | PRLD |
|---|---|---|
| Relative Strength Index (RSI) | 32.13 | 54.14 |
| Support Level | $1.69 | $1.30 |
| Resistance Level | $1.92 | $1.72 |
| Average True Range (ATR) | 0.08 | 0.16 |
| MACD | -0.01 | 0.02 |
| Stochastic Oscillator | 15.58 | 97.65 |
DHI Group Inc is a provider of artificial intelligence-powered software products, online tools and services to deliver career marketplaces to candidates and employers globally. DHI's brands includes Dice and Clearance Jobs enable recruiters and hiring managers to efficiently search, match and connect with skilled technologists in specialized fields, particularly technology and those with active government security clearances. The company derive the majority of revenue came from the sale of recruitment packages, which allow customers to promote jobs on websites and source candidates through their resume databases. Recruitment packages are typically provided through contractual arrangements with annual, quarterly or monthly payment terms.
Prelude Therapeutics Incorp is a clinical stage precision oncology company focused on discovering and developing small molecule therapies optimized to target the key driver mechanisms in cancers with high unmet needs. The company's pipeline includes four candidates currently in clinical development: PRT1419, a potent, selective inhibitor of MCL1; PRT2527, a potent and selective CDK9 inhibitor, PRT3645, a next-generation CDK4/6 inhibitor, and PRT3789 a first-in-class SMARCA2/BRM protein degrader.